Inhalable liposomes for treating lung diseases: clinical development and challenges

Pranav Ponkshe; Sheng Feng; Chalet Tan

doi:10.1088/1748-605X/ac0c0c

Inhalable liposomes for treating lung diseases: clinical development and challenges

Biomed Mater. 2021 Jul 2;16(5). doi: 10.1088/1748-605X/ac0c0c.

Authors

Pranav Ponkshe¹, Sheng Feng¹, Chalet Tan¹

Affiliation

¹ Department of Pharmaceutics and Drug Delivery, University of Mississippi School of Pharmacy, University, Mississippi 38655, The United States.

PMID: 34134097
DOI: 10.1088/1748-605X/ac0c0c

Abstract

Inhalation delivery of liposomal drugs has distinct advantages for the treatment of pulmonary diseases. Inhalable liposomes of several drugs are currently undergoing clinical trials for a range of indications in the lungs. Herein, general principles of pulmonary delivery as well as the clinical development of inhalable liposomal drugs are reviewed.

Keywords: inhalation; liposomes; pulmonary delivery.

Publication types

Review

MeSH terms

Administration, Inhalation*
Animals
Drug Delivery Systems*
Humans
Liposomes* / administration & dosage
Liposomes* / pharmacokinetics
Liposomes* / therapeutic use
Lung Diseases / drug therapy*
Mice

Substances

Liposomes